research roundup

These 3 Houston researchers are revolutionizing health science innovation

From biomolecular research to oral cancer immunotherapy, here are three research projects to watch out for in Houston. Photo via Getty Images

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, a couple local scientists are honored by awards while another duo of specialists tackle a new project.

University of Houston professor recognized with award

Mehmet Orman of UH has been selected to receive an award for his research on persister cells. Photo via UH.edu

Mehmet Orman, assistant professor of chemical and biomolecular engineering at the University of Houston Cullen College of Engineering has been honored with a Faculty Early Career Development Award from the National Science Foundation. The award comes with a $500,000 grant to study persister cells — cells that go dormant and then become tolerant to extraordinary levels of antibiotics.

"Nearly all bacterial cultures contain a small population of persister cells," says Orman in a news release. "Persisters are thought to be responsible for recurring chronic infections such as those of the urinary tract and for creating drug-resistant mutants."

Previously, Orman developed the first methods to directly measure the metabolism of persister cells. He also developed cell sorting strategies to segregate persisters from highly heterogeneous bacterial cell populations, and, according to the release, he will be using his methods in the NSF research project.

Houston researchers collaborate on oral cancer innovation

Dr. Simon Young of UTHealth and Jeffrey Hartgerink of Rice University are working on a new use for an innovative gel they developed. Photo via Rice.edu

Two Houston researchers — chemist and bioengineer Jeffrey Hartgerink at Rice University and Dr. Simon Young at the University of Texas Health Science Center at Houston — have again teamed up to advance their previous development of a sophisticated hydrogel called STINGel. This time, they are using it to destroy oral cancer tumors.

SynerGel combines a pair of antitumor agents into a gel that can be injected directly into tumors. Once there, the gel controls the release of its cargo to not only trigger cells' immune response but also to remove other suppressive immune cells from the tumor's microenvironment. The duo reported on the technology in the American Chemical Society journal ACS Biomaterials Science & Engineering.

SynerGel, combines a pair of antitumor agents into a gel that can be injected directly into tumors, where they not only control the release of the drugs but also remove suppressive immune cells from the tumor's microenvironment.

"We are really excited about this new material," Hartgerink says in a news release. "SynerGel is formulated from a specially synthesized peptide which itself acts as an enzyme inhibitor, but it also assembles into a nanofibrous gel that can entrap and release other drugs in a controlled fashion.

In 2018, the pair published research on the use of a multidomain peptide gel — the original STINGel — to deliver ADU-S100, an immunotherapy drug from a class of "stimulator of interferon gene (STING) agonists."

The research is supported by the Oral and Maxillofacial Surgery Foundation, the National Institutes of Health, the Welch Foundation, the National Science Foundation and the Mexican National Council for Science and Technology.

Texas Heart Institute researcher honored by national organization

Dr. James Martin of Texas Heart Institute has been named a senior member of the National Academy of Inventors. Photo courtesy of THI

The National Academy of Inventors have named Houston-based Texas Heart Institute's Dr. James Martin, director of the Cardiomyocyte Renewal Lab, a senior member.

Martin is an internationally recognized developmental and regenerative biologist and his research is focused on understanding how signaling pathways are related to development and tissue regeneration.

"Dr. Martin has long been a steward of scientific advancement and has proven to be a tremendous asset to the Texas Heart Institute and to its Cardiomyocyte Renewal Lab through his efforts to translate fundamental biological discoveries in cardiac development and disease into novel treatment strategies for cardiac regeneration," says Dr. Darren Woodside, vice president for research at THI, in a news release. "Everyone at the Texas Heart Institute is thrilled for Dr. Martin, whose induction into the NAI as a Senior Member is well-deserved."

Martin has authored over 170 peer-reviewed papers in top journals he holds nine U.S. patents and applications, including one provisional application, all of which have been licensed to Yap Therapeutics, a company he co-founded.

The full list of incoming NAI Senior Members, which includes three professionals from the University of Houston, is available on the NAI website.

Trending News

Building Houston

 
 

With fresh funding, this Houston and Canada-based company has made an acquisition. Courtesy of Validere

After raising $43 million in funding for its series B round, Validere, a commodity management platform for the energy industry, has acquired Clairifi, whose technology helps energy businesses comply with environmental and regulatory requirements. Financial terms weren’t disclosed.

The funding round was closed in March and was led by Mercuria Energy and select funds and accounts managed by BlackRock, with participation from Nova Fleet, Pioneer Fund and NGIF Cleantech Ventures, as well as existing investors, including Wing VC and Greylock Partners, according to a news release.

“Validere’s mission is to ensure human prosperity through energy that is plentiful, sustainable and efficiently delivered," says Nouman Ahmad, Validere co-founder and CEO. "We facilitate this through integrating our customers’ core business with new environmental initiatives. In order to manage the energy transition well, environmental attributes cannot be managed in a silo, they need to be integrated in the day-to-day operations and commercial decisions."

Validere is based in Calgary, Alberta, and has its United States presence based in Houston. Clairifi also is based in Calgary. According to the company, the purchase of Clairifi strengthens Validere’s ESG (environmental, social, and governance) offerings.

“Companies across the energy supply chain are often burdened by the arduous task of compliance reporting, a time-intensive process that is usually performed manually in Excel spreadsheets by costly environmental consultants,” Validere says in a news release announcing the Clairifi deal. “These issues are coupled with constantly changing environmental, social and governance (ESG) policies, as well as disorganized data, which can cause confusion over meeting reporting requirements.”

Validere says that thanks to the integration of Clairifi, businesses can easily comply with current and future regulations from the U.S. Securities and Exchange Commission (SEC), and can access a central platform to accurately measure, manage, and forecast emissions strategies.

“The implementation of costs on carbon and emission reduction requirements introduce new immediate and long-term consequences that cascade from the field to head office,” says Corey Wood, co-founder and CEO of Clairifi. “While regulatory compliance is often considered a burden on industry, requiring resources and continuous innovation, if we are well-prepared, these challenges may be used as catalysts to revive, refresh and improve.”

As part of the acquisition, Wood has joined Validere as vice president of emissions, regulatory, and carbon strategy.

Trending News